---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-104550"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:56:12.793417+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma reports positive Phase 1 data for oral GLP-1R agonist TERN-601; max placebo-adjusted weight loss 4.9%

## Summary
- TERN-601 achieved 4.9% placebo-adjusted mean weight loss at 740 mg QD over 28 days (p<0.0001); 5.5% absolute mean loss.
- 67% of top-dose participants lost ≥5% baseline body weight; no treatment-related dose interruptions or discontinuations.
- Over 95% of AEs were mild; all GI events mild-to-moderate; no serious AEs or clinically meaningful lab/vital changes.
- Company plans to initiate Phase 2 in 2025, with optimal dose range identified and no additional dose exploration needed.
- Terns highlights distinct drug properties (low solubility, high gut permeability, low free fraction) as potential advantages over other oral GLP-1R agonists.

## SEC filing metadata
- accession: 0000950170-24-104550
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017024104550/0000950170-24-104550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017024104550/tern-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-104550
- JSON: https://secwatch.observer/filing/0000950170-24-104550.json
- Plain text: https://secwatch.observer/filing/0000950170-24-104550.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.